Pfizer Cuts 2025 Revenue Guidance to About $62.0 Billion, Sets 2026 EPS at $2.80-$3.00
Pfizer lowered its full-year 2025 revenue guidance to approximately $62.0 billion from $61.0 to $64.0 billion, while reaffirming its 2025 adjusted diluted EPS guidance of $3.00 to $3.15. The company also issued 2026 guidance calling for revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, below the 2025 EPS range, citing a higher expected tax rate and about $1.5 billion of revenue loss from loss of exclusivity.
Key points
- 2025 revenue guidance revised to approximately $62.0 billion from $61.0 to $64.0 billion; 2025 adjusted diluted EPS guidance of $3.00 to $3.15 reaffirmed
- 2026 adjusted diluted EPS guidance of $2.80 to $3.00, with an effective tax rate of approximately 15% versus approximately 11% in 2025
- 2026 revenue guidance of $59.5 to $62.5 billion includes about $1.5 billion lower COVID-19 product revenue and about $1.5 billion negative impact from loss of exclusivity
- 2026 adjusted SI&A and R&D expenses combined expected at $23.0 to $25.0 billion; guidance assumes no share repurchases in 2025 or 2026
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 16, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.